文献速递乳腺癌

西德研究组PlanB试验:HER2阴性早期乳腺癌辅助表柔比星联合环磷酰胺序贯多西他赛四周期对比多西他赛联合环磷酰胺六周期

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
PubMed 文献 · J Clin Oncol · 2019-02-20

PlanB试验评估HER2阴性早期乳腺癌中无蒽环类方案TC(多西他赛+环磷酰胺6周期)对比EC-T(表柔比星+环磷酰胺4周期序贯多西他赛4周期)。意向治疗人群2449例,中位随访60个月,5年DFS EC-T组89.6% vs TC组89.9%,5年OS 94.5% vs 94.7%,DFS差异在预设非劣效界值4.4%内。

要点

  • 5年DFS EC-T组89.6% vs TC组89.9%,差异在非劣效界值4.4%内。
  • 5年OS EC-T组94.5% vs TC组94.7%,两组相似。
  • TC组报告5例治疗相关死亡,EC-T组报告1例。

核心结论

  • PlanB试验中TC方案与EC-T方案的5年结局同样优异。
  • 6周期TC是HER2阴性早期乳腺癌中pN0高基因组风险或pN1基因组中高危疾病的有效/安全选择。

研究设计与样本

  • 西德研究组PlanB试验为随机对照试验,比较EC-T与TC方案。
  • 入组pT1至pT4c、所有pN+及pN0高危HER2阴性早期乳腺癌患者。
  • 高危pN0定义为满足以下一项或多项:pT大于2、分级2至3、高尿激酶型纤溶酶原激活物/纤溶酶原激活物抑制剂-1、激素受体阴性、年龄小于35岁。
  • HR阳性肿瘤经复发评分(RS)检测,RS≤11的pN0至pN1疾病推荐省略化疗。
  • 意向治疗人群2449例(EC-T组1227例 vs TC组1222例),安全性人群EC-T组1167例 vs TC组1178例。

主要发现

  • 中位随访60个月,5年DFS EC-T组89.6%(95%CI 87.9%至91.5%)vs TC组89.9%(95%CI 88.1%至91.8%)。
  • 5年OS EC-T组94.5%(95%CI 93.1%至95.9%)vs TC组94.7%(95%CI 93.3%至96.1%)。
  • DFS差异在原始试验设计的非劣效界值4.4%内。
  • 安全性人群中完成治疗比例EC-T组87.5% vs TC组93.0%。
  • TC组报告5例治疗相关死亡,EC-T组报告1例;EC-T组有更严重不良事件趋势。

关键数值与推荐

  • 主要终点为无病生存期(DFS),次要终点为总生存期(OS)和安全性。
  • 非劣效界值为4.4%,协议规定P=.05。
  • EC-T方案:表柔比星90mg/m²+环磷酰胺600mg/m²×4周期,序贯多西他赛100mg/m²×4周期,每3周一次。
  • TC方案:多西他赛75mg/m²+环磷酰胺600mg/m²×6周期,每3周一次。

临床怎么用

  • 作者认为6周期TC是HER2阴性早期乳腺癌中pN0高基因组风险或pN1基因组中高危疾病的有效/安全选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS: Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)90/cyclophoshamide (C)600 followed by four cycles of docetaxel (T)100 or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULTS: Of the 3,198 registered patients, 348 (RS ≤ 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v 60.8%; pN0, 58.2% v 59.5%; pT1, 57.6% v 52.3%; HR positive, 81.4% v 82.2%; RS greater than 25 [in HR-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v 89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v 94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), despite a trend toward more-severe adverse events in the latter. Interaction analysis revealed no predictive trends with respect to key factors, including triple-negative, luminal A/B-like, pN, age, and RS status. CONCLUSION: In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T were equally excellent. Six cycles of TC is an effective/safe option in human epidermal growth factor receptor 2-negative EBC with pN0 high genomic risk or pN1 EBC with genomically intermediate- to high-risk disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nitz U, Gluz O, Clemens M, et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol. 2019. PMID: 30785826. doi:10.1200/JCO.18.00028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。